Amyotrophic Lateral Sclerosis Treatment Market to Reach $3.5 Billion by 2035

Amyotrophic Lateral Sclerosis treatment market was valued at $1.5 billion in 2025 and is projected to reach $3.5 billion by 2035, growing at a CAGR of 8.9% during 2026–2035. The market is experiencing steady expansion due to the rising prevalence of neurodegenerative disorders, increasing adoption of disease-modifying therapies, and growing investment in gene-targeted treatment approaches. Advancements in precision medicine and expanding research activities focused on rare neurological diseases are further supporting the development of innovative ALS therapeutics. Pharmaceutical companies are increasingly prioritizing antisense oligonucleotide therapies, neuroprotective drugs, and targeted biologics to address the significant unmet clinical needs associated with ALS. In addition, supportive regulatory frameworks and orphan-drug incentives are accelerating commercialization activities across major healthcare markets.

Browse the full report description of “Amyotrophic Lateral Sclerosis Treatment Market Size, Share & Trends Analysis Report by Drug Type (Disease-Modifying Therapies, Symptomatic Treatments, Combination Therapies), by Treatment Type (Pharmacological Treatment, Cell-Based Therapy, Gene Therapy, Supportive & Palliative Care, Assistive Respiratory Therapy), by End User (Hospitals, Neurology Clinics, Ambulatory Care Centers, Home Care Settings, Research & Academic Institutes), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/amyotrophic-lateral-sclerosis-treatment-market

According to the World Health Organization (WHO), more than 3 billion people worldwide were living with neurological conditions in 2021, making neurological disorders the leading cause of illness and disability globally. The organization also reported an 18% increase in the global neurological disease burden since 1990, primarily driven by aging populations and increasing exposure to environmental and lifestyle-related risk factors. This rising burden of neurological disorders is expected to significantly increase demand for advanced neurodegenerative disease therapies, including ALS treatments. Furthermore, growing healthcare expenditure on rare diseases, expanding clinical research programs, and increasing awareness regarding early diagnosis are contributing to long-term growth opportunities in the Amyotrophic Lateral Sclerosis treatment market.

Innovation Leaders Advancing the Amyotrophic Lateral Sclerosis Treatment Market

The key players in the Amyotrophic Lateral Sclerosis treatment market include Roche, Novartis, Sanofi, Takeda Pharmaceutical Company, and Regeneron Pharmaceuticals, among others. These companies are increasingly investing in antisense therapies, disease-modifying drugs, and cell-based neurology treatments to strengthen their competitive position. Strategic collaborations with biotechnology firms and academic institutes are accelerating next-generation ALS therapy development. Companies are also expanding orphan-drug pipelines and increasing neurological research investments to address unmet treatment demand. Regulatory incentives and accelerated approval pathways are further supporting innovation in ALS therapeutics globally.

• In December 2025, Shionogi announced the acquisition of global rights to RADICAVA and RADICAVA ORS (edaravone) from Tanabe Pharma to strengthen its rare disease portfolio and expand its presence in the ALS treatment market. The acquisition includes intellectual property and commercialization rights for approved ALS therapies across major regions, supporting long-term innovation and continuity of care for ALS patients. The move highlights increasing strategic investments in rare neurodegenerative disease therapeutics and orphan-drug commercialization.

• In December 2025, Biogen announced that JAMA Neurology published long-term Phase 3 VALOR and open-label extension study results for QALSODY (tofersen) in SOD1-ALS patients. The findings showed slower decline in clinical function, strength, and respiratory performance, along with reduced risk of death or permanent ventilation, supporting continued advancement of precision ALS therapies.
• In January 2024, Ionis Pharmaceuticals announced continued momentum in its neurology pipeline, highlighting the accelerated approval and commercialization progress of QALSODY (tofersen) for SOD1-associated Amyotrophic Lateral Sclerosis (ALS). The company also emphasized ongoing regulatory milestones and Phase 2 development activities for additional ALS therapies, strengthening its position in the global ALS treatment market.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-

• By Drug Type
• By Treatment Type
• By End User
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape: Roche, Novartis, Sanofi, Takeda Pharmaceutical Company, and Regeneron Pharmaceuticals, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Amyotrophic Lateral Sclerosis Treatment Market Report Segment

By Drug Type

• Disease-Modifying Therapies
• Symptomatic Treatments
• Combination Therapies

By Treatment Type

• Pharmacological Treatment
• Cell-Based Therapy
• Gene Therapy
• Supportive & Palliative Care
• Assistive Respiratory Therapy

By End User

• Hospitals
• Neurology Clinics
• Ambulatory Care Centers
• Home Care Settings
• Research & Academic Institutes

Global Amyotrophic Lateral Sclerosis Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/amyotrophic-lateral-sclerosis-treatment-market